There is an active and bitter debate
going on right now as to whether the drug Ivermectin is a successful
treatment for Covid-19. Some doctors are seemingly throwing caution
to the wind and writing prescriptions for Ivermectin as a treatment
protocol for their patients infected with the novel Covid-19 virus.
Many report remarkable success stories. So what's the debate about?
The counter-argument is generally that
Ivermectin is strictly for the treatment of parasites in animals...
but there are literally dozens of off-label uses with peer-reviewed
studies than demonstrate the broad efficacy of this drug for humans.
It is already known to kill 22 different viruses. This was testified
to in front of Congress in December of 2020 by qualified and
competent medical authorities. It cures the flu. Some report the
quick turn-around of Covid symptoms with its use. It probably cures
smallpox and polio too; probably even Ebola and malaria. The people
who created it were awarded a Nobel Prize. Over 4 billion doses of
it have already been given to humans for various treatments with
remarkable success... and it has the lowest death rate per dose of
any drug that you can suggest over the last century. Furthermore, it
is virtually impossible to overdose on it, so that when all things
are considered it may be one of the safest things you can take for
any viral infection.
Those receiving Ivermectin who have
been infected with the virus or treated with one of the vaccines with
spiked proteins and graphene oxide are finding that the drug is
binding itself to these two foreign agents and flushing them out of
the body through the gut, no matter what tissues throughout the body
they have become embedded in.
Ivermectin is an interesting substance,
derived from a source never before tapped as an aid to humans. Its
creators looked at the enzymatic products of nematodes in the soil;
they studied what these enzymes were doing to the surrounding area of
the soil and came up with powerful medicine for humans. Perhaps its
greatest potential benefit may be its use as a cure for cancer.
Scientists have been taking cancer
patients, treating them with Ivermectin, and discovering the quick
and total eradication of nascent cancer cells throughout the body.
Initial findings are that it erodes tumors in a safe way. The
highlights of a report in ScienceDirect.com are as follows:
• Ivermectin effectively suppresses the proliferation and
metastasis of cancer cells and promotes cancer cell death at doses
that are nontoxic to normal cells.
• Ivermectin
shows excellent efficacy against conventional chemotherapy
drug-resistant cancer cells and reverses multidrug resistance.
• Ivermectin
combined with other chemotherapy drugs or targeted drugs has powerful
effects on cancer.
• The structure
of cross-talk centered on PAK1 kinase reveals the mechanism by which
ivermectin regulates multiple signaling pathways.
• Ivermectin
has been used to treat parasitic diseases in humans for many years
and can quickly enter clinical trials for the treatment of tumors.
Their supporting Abstract reads as
follows:
Ivermectin is
a macrolide anti-parasitic drug with a 16-membered ring that is
widely used for the treatment of many parasitic diseases such as
river blindness, elephantiasis and scabies. Satoshi Omura and
William C. Campbell won the 2015 Nobel Prize in Physiology or
Medicine for the discovery of the excellent efficacy of ivermectin
against parasitic diseases. Recently, ivermectin has been reported
to inhibit the proliferation of several tumor cells by regulating
multiple signaling pathways. This suggests that ivermectin may be
an anticancer drug with great potential.
Ivermectin has
powerful anti-tumor effects, including the inhibition of
proliferation, metastasis, and angiogenic activity, in a variety of
cancer cells. This may be related to the regulation of multiple
signaling pathways by ivermectin through PAK1 kinase. On the other
hand, ivermectin promotes programmed cancer cell death, including
apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and
autophagy is mutually regulated. Interestingly, ivermectin can also
inhibit tumor stem cells and reverse multi-drug resistance and exerts
the optimal effect when used in combination with other chemotherapy
drugs.
Dr.
William Makis, one of the most well-known critics of the failed
response to the COVID-19 pandemic, has been an enthusiastic advocate
for the use of Ivermectin and mebendazole in treating a wide array of
cancers. Dr.
Makis listed 20 studies that show the potential for Ivermectin in
fighting cancer:
Here
are recent studies on IVERMECTIN use in certain types of cancer:
BLADDER
CANCER– (2024 Fan et al) – Ivermectin Inhibits Bladder Cancer
Cell Growth and Induces Oxidative Stress and DNA Damage
LUNG
CANCER– (2024 Man-Yuan Li et al) – Ivermectin induces
nonprotective autophagy by downregulating PAK1 and apoptosis in
lung adenocarcinoma cells
GLIOMA–
(2024 Xing Hu et al) – Ivermectin as a potential therapeutic
strategy for glioma
MULTIPLE
MYELOMA– (2024 Yang Song et al) – Gene signatures to
therapeutics: Assessing the potential of ivermectin against
t(4;14) multiple myeloma
OVARIAN
CANCER– (2023 Jawad et al) – Ivermectin augments the
anti-cancer activity of pitavastatin in ovarian cancer cells
PROSTATE
CANCER –(2022 Lu et al) – Integrated analysis reveals FOXA1
and Ku70/Ku80 as targets of ivermectin in prostate cancer
COLON
CANCER– (2022, Alghamdi et al) – Efficacy of ivermectin
against colon cancer induced by dimethylhydrazine in male wistar
rats
PANCREATIC
CANCER– (2022 Lee et al) – Ivermectin and gemcitabine
combination treatment induces apoptosis of pancreatic cancer
cells via-mitochondrial dysfunction
MELANOMA–
(2022 Zhang et al) – Drug repurposing of ivermectin abrogates
neutrophil extracellular traps and prevents melanoma metastasis
CERVICAL
CANCER– (2022, Qabbus et al) – Ivermectin-induced cell death
of cervical cancer cells in vitro a consequence of precipitate
formation in culture media
HEPATOCELLULAR
CARCINOMA– (2022 Lu et al) – Ivermectin synergizes sorafenib
in hepatocellular carcinoma via targeting multiple oncogenic
pathways
OSTEOSARCOMA–
(2022 Hu et al) – Repurposing Ivermectin to augment
chemotherapy’s efficacy in osteosarcoma
GASTRIC
CANCER– (2021 Rabben et al) – Computational drug repositioning
and experimental validation of ivermectin in treatment of gastric
cancer
LEUKEMIA–
(2020, de Castro et al) – Continuous high-dose ivermectin
appears to be safe in patients with acute myelogenous leukemia and
could inform clinical repurposing for COVID-19 infection
ESOPHAGEAL
SCC– (2020, Chen et al) – Ivermectin suppresses tumor growth
and metastasis through degradation of PAK1 in oesophageal squamous
cell carcinoma
CHOLANGIOCARCINOMA–
(2019 Intyuod et al) – Anti-parasitic drug ivermectin exhibits
potent anticancer activity against gemcitabine-resistant
cholangiocarcinoma in vitro
BREAST
CANCER STEM CELLS –(2018 Dominguez-Gomez et al) – Ivermectin
as an inhibitor of cancer stem-like cells
CML
(CHRONIC MYELOID LEUKEMIA)– (2018 Wang et al) –
Antibiotic ivermectin selectively induces apoptosis in chronic
myeloid leukemia through inducing mitochondrial dysfunction and
oxidative stress
RENAL
CELL CARCINOMA– (2017 Zhu et al) – Antibiotic ivermectin
preferentially targets renal cancer through inducing mitochondrial
dysfunction and oxidative damage
GLIOBLASTOMA–
(2016 Liu et al) – Anthelmintic drug ivermectin inhibits
angiogenesis, growth and survival of glioblastoma through inducing
mitochondrial dysfunction and oxidative stress
Dr.
Makis makes it clear that he believes Ivermectin could be a
valuable tool in the battle against cancer and explains why the
medical establishment is in no hurry to explore Ivermectin’s
potential:
IVERMECTIN
has proven anti-cancer activity against some 20 cancer types,
although these are pre-clinical studies. We will never see
clinical studies because Ivermectin is off patent and cheap. Merck,
which used to have a patent on Ivermectin, has partnered with Moderna
on mRNA Cancer Vaccines, estimated to cost 400,000 GBP per
treatment. Ivermectin studies on mice include: Breast cancer, Colon
cancer, glioblastoma, glioma and leukemia. I have not seen IVERMECTIN
studies on Lymphoma, Testicular Cancer, Sarcomas. IVERMECTIN acts on
Cancer mainly by inhibiting signaling pathways involved in cancer
proliferation (Akt, Wnt, mTOR) and by inhibiting CANCER STEM CELLS.
Dr.
Makis is one of the trusted medical professionals talking about the
potential of Ivermectin. According to the McCullough
Foundation a new study confirms the early returns on Ivermectin
are positive:
The
study titled “A Review of Ivermectin Use in Cancer Patients: Is it
Time to Repurpose the Ivermectin in Cancer Treatment?” was
just published in the journal Acta Poloniae Pharmaceutica –
Drug Research…Based on the most comprehensive systematic review of
ivermectin use in cancer patients to date, ivermectin appears to be
safe—even in individuals undergoing active chemotherapy. Its broad
range of anticancer mechanisms demonstrated in preclinical models,
combined with anecdotal reports of cancer-related improvements,
support its candidacy for repurposing as an oncologic therapy.
Well-designed, large-scale clinical trials should be launched as soon
as possible to properly assess ivermectin’s potential against
cancer.
Indeed,
ivermectin in concert with mebendazole has shown even more
promise in treating a wide variety of cancers.
We all need to question, question,
question further whenever either the authorities or the media object
to or attempt to regulate against the use of this drug without a
reasonable, scientific-based explanation, and demand support of their
argument.